De Kock M, Famenne F, Deckers G, Scholtes J L
Department of Anesthesiology, Catholic University of Louvain Medical, St. Luc Hospital, Brussels, Belgium.
Anesth Analg. 1995 Dec;81(6):1154-62. doi: 10.1097/00000539-199512000-00007.
This study contrasts the efficacy and side effects of epidural clonidine and sufentanil in the perioperative period. Using a randomized, prospective, double-blind study design, 40 patients undergoing abdominal surgery under propofol/nitrous oxide anesthesia were enrolled. Before anesthesia, an epidural catheter was inserted at the L1-L2 interspace. At induction of anesthesia, the patients received epidurally either clonidine (4 micrograms/kg in 10 mL) infused in 20 min followed by a 2-micrograms.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 1) or sufentanil (0.5 microgram/kg in 10 mL) in 20 min followed by a 0.25-microgram.kg-1.h-1 infusion (5 mL/h) during 12 h (Group 2). Intraoperatively, increases in arterial blood pressure and heart rate not responding to propofol bolus (0.5 mg/kg) were treated with a bolus of intravenous (IV) sufentanil 0.035 microgram/kg. Postoperatively, IV sufentanil boluses (5 micrograms) were given through a patient-controlled analgesia (PCA) device. Postoperative analgesia was assessed by recording the IV PCA sufentanil requirements and the patients' visual analog scale (VAS) at 3, 6, 12, 18, 24, 36, and 48 h. Sedation analog scales and side effects were also recorded. Plasma clonidine and sufentanil concentrations were measured after 20 min and 6, 12, and 24 h. The number of reinjections of propofol (n = 1.6 +/- 1.6 in Group 1 vs 6.5 +/- 4.0 in Group 2) and of IV sufentanil (n = 0.6 +/- 0.8 in Group 1 vs 3.8 +/- 3.7 in Group 2) was significantly reduced (P < 0.001) in the epidural clonidine group. In the early postoperative period, pain scores and rescue analgesic requirements were very low in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究对比了围手术期硬膜外使用可乐定和舒芬太尼的疗效及副作用。采用随机、前瞻性、双盲研究设计,纳入40例在丙泊酚/氧化亚氮麻醉下行腹部手术的患者。麻醉前,于L1-L2间隙置入硬膜外导管。麻醉诱导时,患者硬膜外给予可乐定(4微克/千克,溶于10毫升),20分钟内输注完毕,随后以2微克·千克⁻¹·小时⁻¹的速度输注(5毫升/小时),持续12小时(第1组),或给予舒芬太尼(0.5微克/千克,溶于10毫升),20分钟内输注完毕,随后以0.25微克·千克⁻¹·小时⁻¹的速度输注(5毫升/小时),持续12小时(第2组)。术中,对丙泊酚推注注注注(0.5毫克/千克)无反应的动脉血压和心率升高,用0.035微克/千克静脉推注舒芬太尼处理。术后,通过患者自控镇痛(PCA)装置给予静脉推注舒芬太尼(5微克)。通过记录静脉PCA舒芬太尼需求量以及患者在术后3、6、12、18、24、36和48小时的视觉模拟评分(VAS)来评估术后镇痛效果。还记录了镇静模拟评分和副作用。在20分钟以及6、12和24小时后测量血浆可乐定和舒芬太尼浓度。硬膜外可乐定组丙泊酚再次注射次数(第1组n = 1.6±1.6,第2组n = 6.5±4.0)和静脉舒芬太尼再次注射次数(第1组n = 0.6±0.8,第2组n = 3.8±3.7)显著减少(P < 0.001)。术后早期,两组的疼痛评分和补救性镇痛需求量均很低。(摘要截选至250词)